SR9009 — Safety, Research, Risks & Legal Status

Not medical advice. SR9009 is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	Stenabolic, SR-9009
Category	SARM
poor_bioavailability	Well-documented poor oral bioavailability, limiting efficacy of oral products
research_tool	Developed at Scripps as a scientific research probe, not intended for therapeutic use
rev_erb_agonist	Acts on nuclear Rev-erb proteins, not androgen receptors or traditional SARM pathways
US legal status	SR9009 is not approved by the FDA for any use, and it is illegal to market or sell it as a dietary supplement. Products are sold as research chemicals not for human consumption, and the FDA has warned that SARM-type products carry serious risks. It is prohibited at all times in sport under the WADA list.

What is SR9009?

SR9009 (Stenabolic) is not a SARM but a Rev-erb agonist that influences circadian and metabolic pathways, and it is commonly grouped and sold with SARMs. It was developed as a research tool rather than a clinical drug.

How it works

SR9009 is a synthetic Rev-erb agonist that activates the nuclear Rev-erb alpha and beta receptors, which regulate circadian rhythm genes and metabolic pathways including lipid and glucose metabolism. It influences BMAL1, a key circadian-rhythm protein, and affects mitochondrial biogenesis. The compound was developed as a research probe, not as a therapeutic agent.

Background & history

SR9009 (stenabolic) was developed by Dr. Thomas Burris and colleagues at The Scripps Research Institute as a tool to study Rev-erb biology and circadian metabolism. It was never intended for human use and no development toward clinical application occurred. The compound entered bodybuilding and performance-enhancement communities despite its research-only status and bioavailability limitations.

What the research says

Research suggests SR9009 affects metabolism and endurance in animal studies by acting on Rev-erb proteins. A major limitation is that it has poor oral bioavailability, so much of the animal data used injection, and there are no human safety trials.

Reported effects

Reported metabolic and endurance effects in animal studies
Studied effects on circadian and lipid metabolism in mice
Reported fat-loss effects by users
Studied as a Rev-erb agonist research tool
Reported improved workout recovery in user communities
Studied effects on mitochondrial function in preclinical models

Dosing & administration (informational)

In animal studies, SR9009 was typically injected due to poor oral bioavailability; doses varied widely depending on experimental design. Oral bioavailability in humans is likely minimal to negligible, making oral products unlikely to produce the metabolic effects seen in injected animal studies. No human pharmacokinetics or dose studies exist.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Has poor oral bioavailability, meaning oral products are unlikely to deliver the effects seen in injected animal studies
Has no human safety trials, so risks in people are unknown
Often sold alongside genuine SARMs, which carry hormonal and organ risks
Marketed with claims that outrun the limited and largely preclinical evidence
Prohibited at all times in sport under the WADA list
May cause gastrointestinal distress or other metabolic effects in users

Drug & supplement interactions

May interact with medications affecting circadian or metabolic pathways
Potential for additive effects if combined with other weight-loss or metabolic agents
Limited data on interactions with supplements or natural compounds affecting Rev-erb
Unknown interactions with most drugs given lack of human pharmacology
Bioavailability issues may prevent meaningful drug interactions if oral absorption is negligible

Who should avoid it

Avoid if there is metabolic disorder or glucose-control problems, as Rev-erb effects are unpredictable
Avoid concurrent use with other metabolic modulators or SARMs
Avoid if circadian rhythm disorders are present without clinician guidance
Avoid if tested in sport or under workplace drug screening
Avoid in oral form given documented poor bioavailability makes efficacy unlikely

How it is commonly combined

SR9009 is commonly marketed for stacking with SARMs or other compounds for enhanced fat loss and endurance. However, such combinations have never been studied and stacking multiplies unknown risks. The poor oral bioavailability of SR9009 itself raises questions about whether effects observed in stacks are genuine.

Legal & regulatory. SR9009 is not approved by the FDA for any use, and it is illegal to market or sell it as a dietary supplement. Products are sold as research chemicals not for human consumption, and the FDA has warned that SARM-type products carry serious risks. It is prohibited at all times in sport under the WADA list.

Quality & harm reduction

R
e
q
u
i
r
e
a
t
h
i
r
d
-
p
a
r
t
y
c
e
r
t
i
f
i
c
a
t
e
o
f
a
n
a
l
y
s
i
s
(
C
O
A
)
c
o
n
f
i
r
m
i
n
g
i
d
e
n
t
i
t
y
a
n
d
p
u
r
i
t
y
,
n
o
t
i
n
g
t
h
a
t
o
r
a
l
b
i
o
a
v
a
i
l
a
b
i
l
i
t
y
i
s
s
u
e
s
m
a
k
e
p
u
r
i
t
y
t
e
s
t
i
n
g
a
l
o
n
e
i
n
s
u
f
f
i
c
i
e
n
t
.
I
n
d
e
p
e
n
d
e
n
t
a
n
a
l
y
s
e
s
f
r
e
q
u
e
n
t
l
y
f
i
n
d
s
u
c
h
p
r
o
d
u
c
t
s
m
i
s
l
a
b
e
l
e
d
o
r
c
o
n
t
a
i
n
i
n
g
u
n
l
i
s
t
e
d
d
r
u
g
s
o
r
S
A
R
M
s
m
i
x
e
d
i
n
.
G
i
v
e
n
t
h
e
l
a
c
k
o
f
h
u
m
a
n
d
a
t
a
,
a
n
y
u
s
e
s
h
o
u
l
d
i
n
v
o
l
v
e
c
l
i
n
i
c
i
a
n
o
v
e
r
s
i
g
h
t
a
n
d
b
l
o
o
d
w
o
r
k
m
o
n
i
t
o
r
i
n
g
.
T
r
e
a
t
u
n
r
e
g
u
l
a
t
e
d
p
r
o
d
u
c
t
s
a
s
p
o
t
e
n
t
i
a
l
l
y
c
o
n
t
a
m
i
n
a
t
e
d
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

Does SR9009 work as an oral supplement?

Its poor oral bioavailability means oral products are unlikely to reach the levels that produced effects in injected animal studies.

Is SR9009 a SARM?

No. It is a Rev-erb agonist, but it is commonly marketed and sold with SARMs.

What dose is safe?

We do not provide human dosing guidance. SR9009 is unapproved and any use should involve a qualified clinician.

How does SR9009 affect circadian rhythm?

It activates Rev-erb proteins that regulate BMAL1 and other circadian genes, theoretically shifting metabolic timing, but human effects are entirely unexplored.

Can SR9009 replace sleep or exercise?

No. Marketing claims sometimes suggest metabolic shortcuts, but animal work does not support such claims and no human evidence exists.

References & further reading

PubMed: SR9009 Rev-erb agonist circadian metabolism animal
PubMed: stenabolic oral bioavailability pharmacokinetics Rev-erb
FDA warning on SARMs and unapproved metabolic compounds
WADA Prohibited List: Rev-erb agonists and related compounds
Scripps Research Institute Rev-erb biology circadian research